• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment.在新冠病毒保护和治疗的竞赛中,疫苗和治疗药物研发的最新成果。
J Evid Based Integr Med. 2021 Jan-Dec;26:2515690X211003727. doi: 10.1177/2515690X211003727.
2
Animal models for studying coronavirus infections and developing antiviral agents and vaccines.用于研究冠状病毒感染和开发抗病毒药物和疫苗的动物模型。
Antiviral Res. 2022 Jul;203:105345. doi: 10.1016/j.antiviral.2022.105345. Epub 2022 May 21.
3
SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.严重急性呼吸综合征(SARS)、中东呼吸综合征(MERS)和严重急性呼吸综合征冠状病毒 2(COVID-19)治疗:专利述评。
Expert Opin Ther Pat. 2020 Aug;30(8):567-579. doi: 10.1080/13543776.2020.1772231. Epub 2020 Jun 7.
4
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies.对 COVID-19 目前进展的批判性综述:疫苗、抗病毒药物和治疗性抗体的开发。
J Biomed Sci. 2022 Sep 12;29(1):68. doi: 10.1186/s12929-022-00852-9.
5
Recent advances in potential drug therapies combating COVID-19 and related coronaviruses-A perspective.近期对抗 COVID-19 及相关冠状病毒的潜在药物疗法的进展——一种观点。
Food Chem Toxicol. 2021 Aug;154:112333. doi: 10.1016/j.fct.2021.112333. Epub 2021 Jun 10.
6
Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.新型冠状病毒肺炎、严重急性呼吸综合征和中东呼吸综合征的生物学、临床和流行病学特征,以及 ACE2 的 AutoDock 模拟
Infect Dis Poverty. 2020 Jul 20;9(1):99. doi: 10.1186/s40249-020-00691-6.
7
Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.利用天然化合物靶向 SARS-CoV-2 感染的药物发现的当前方法。
Virus Res. 2020 Dec;290:198169. doi: 10.1016/j.virusres.2020.198169. Epub 2020 Sep 24.
8
Viral Infections of the Upper Airway in the Setting of COVID-19: A Primer for Rhinologists.新型冠状病毒病(COVID-19)背景下的上呼吸道病毒感染:鼻科医生的入门知识。
Am J Rhinol Allergy. 2021 Jan;35(1):122-131. doi: 10.1177/1945892420947929. Epub 2020 Aug 6.
9
[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].[2019冠状病毒病及严重急性呼吸综合征冠状病毒2的诊断、治疗、控制与预防:回归未来]
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592. doi: 10.13345/j.cjb.200115.
10
Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries.新冠病毒疫苗研发和靶向治疗的现状:基础科学发现的影响。
Cardiovasc Pathol. 2021 Jan-Feb;50:107278. doi: 10.1016/j.carpath.2020.107278. Epub 2020 Sep 2.

本文引用的文献

1
An Update on Current Therapeutic Drugs Treating COVID-19.治疗新型冠状病毒肺炎的当前治疗药物最新情况
Curr Pharmacol Rep. 2020;6(3):56-70. doi: 10.1007/s40495-020-00216-7. Epub 2020 May 11.
2
A Review of SARS-CoV-2 and the Ongoing Clinical Trials.SARS-CoV-2 综述及正在进行的临床试验。
Int J Mol Sci. 2020 Apr 10;21(7):2657. doi: 10.3390/ijms21072657.
3
Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines.用于治疗新型冠状病毒肺炎的草药医学与辨证论治:指南快速回顾
Integr Med Res. 2020 Jun;9(2):100407. doi: 10.1016/j.imr.2020.100407. Epub 2020 Mar 29.
4
Clinical trials on drug repositioning for COVID-19 treatment.用于治疗新冠肺炎的药物重新定位的临床试验。
Rev Panam Salud Publica. 2020 Mar 20;44:e40. doi: 10.26633/RPSP.2020.40. eCollection 2020.
5
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
6
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.对于重症新冠病毒感染患者,没有证据表明羟氯喹和阿奇霉素联合使用能实现快速的抗病毒清除或带来临床益处。
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
7
Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases.新型冠状病毒肺炎及相关人类冠状病毒疾病治疗药物和疫苗的研发
ACS Cent Sci. 2020 Mar 25;6(3):315-331. doi: 10.1021/acscentsci.0c00272. Epub 2020 Mar 12.
8
Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective.中药治疗 2019 年新型冠状病毒(SARS-CoV-2)感染患者:综述与展望。
Int J Biol Sci. 2020 Mar 15;16(10):1708-1717. doi: 10.7150/ijbs.45538. eCollection 2020.
9
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19:一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
10
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.基于网络的2019新型冠状病毒(2019-nCoV/SARS-CoV-2)药物重新利用研究
Cell Discov. 2020 Mar 16;6:14. doi: 10.1038/s41421-020-0153-3. eCollection 2020.

在新冠病毒保护和治疗的竞赛中,疫苗和治疗药物研发的最新成果。

A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment.

机构信息

362057University of Gondar, College of Medicine and Health Sciences, Gondar, Ethiopia.

出版信息

J Evid Based Integr Med. 2021 Jan-Dec;26:2515690X211003727. doi: 10.1177/2515690X211003727.

DOI:10.1177/2515690X211003727
PMID:33761791
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8743933/
Abstract

Currently, the coronavirus disease 2019 (COVID-19) is a big challenge to the healthcare systems in the world. Several researchers in the world have immediately carried out clinical investigations for the discovery of vaccines and drugs. Different studies have shown that antiviral measures including small bioactive compounds targeting multifaceted molecular communications take in COVID-19 infection. The drug development archived in this review emphasizes mainly on drugs that are effective for the Management of MERS-CoV, SARS-CoV, and other RNA viruses. The investigation of therapeutic agents for COVID-19 includes anti-inflammatory agents, antibodies, and nucleic acid-based treatments targeting virus gene expression as well as different sorts of vaccines. Numerous patents revealed techniques of these biologics with the potential for treating and preventing coronavirus infections, which may apply to COVID-19. Phase 3 clinical trials such as Sputnik V, AZD1222, mRNA-1273, BNT162b2, Ad5-nCoV, Anti-COVID antibodies, Kevzara; Actemra, Jakafi; Baricitinib, and some others were undergoing in the race for Covid-19 treatment. However, there's still a lack of a review on vaccines and drugs for COVID-19 management. Therefore, this review summarizes different studies that are ongoing in the race for Covid-19 protection and treatment.

摘要

目前,2019 年冠状病毒病(COVID-19)对世界各国的医疗保健系统构成了重大挑战。世界上的几位研究人员立即开展了临床研究,以发现疫苗和药物。不同的研究表明,针对 COVID-19 感染的抗病毒措施包括针对多方面分子通讯的小分子生物活性化合物。本综述中药物开发主要侧重于对中东呼吸综合征冠状病毒(MERS-CoV)、严重急性呼吸综合征冠状病毒(SARS-CoV)和其他 RNA 病毒有效的药物。针对 COVID-19 的治疗剂的研究包括抗炎药、抗体以及针对病毒基因表达的核酸治疗以及各种疫苗。大量专利揭示了这些生物制剂的技术,这些技术具有治疗和预防冠状病毒感染的潜力,可能适用于 COVID-19。Sputnik V、AZD1222、mRNA-1273、BNT162b2、Ad5-nCoV、抗 COVID 抗体、Kevzara;Actemra、Jakafi;巴瑞替尼和其他一些药物正在进行 3 期临床试验,以治疗 COVID-19。然而,对于 COVID-19 管理的疫苗和药物,仍缺乏综述。因此,本综述总结了正在进行的针对 COVID-19 保护和治疗的不同研究。